PHA-543613 is a drug that acts as a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors with a high level of brain penetration and good oral bioavailability. It is under development as a possible treatment for cognitive deficits in schizophrenia.
This page contains content from the copyrighted Wikipedia article "PHA-543613"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
